Tadeusz Kubicki

Has grant

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Związek TXNDC5 i kalretikuliny ze zmniejszeniem stresu ER umożliwiającym opornym komórkom szpiczaka plazmocytowego ominięcie blokady proteasomu.

Open Date: 2019-02-18

Close Date: 2022-02-17

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Pawel Robak

Medical University of Lodz

POLAND

View details

Krzysztof Jamroziak

Institute of Hematology and Transfusion Medicine

POLAND

View details

Benjamin Derman

Assistant Professor

University of Chicago

UNITED STATES

View details

Andrzej J. Jakubowiak

UNITED STATES

View details

Dominik Dytfeld

Professor

Poznan University of Medical Sciences

POLAND

View details

Lidia Usnarska-Zubkiewicz

Wroclaw Medical University

POLAND

View details

Tomasz Wrobel

Wroclaw Medical University

POLAND

View details

Ajay Major

Assistant Professor of Medicine

University of Colorado School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tadeusz Kubicki

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (13)

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone

T-cell exhaustion in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial

<i>HRAS</i> mutation positive multiple myeloma in the type 2 <i>CALR</i> mutation positive essential thrombocythemia: A case report

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Collaborators (8)

Pawel Robak

Krzysztof Jamroziak

Benjamin Derman

Andrzej J. Jakubowiak

Dominik Dytfeld

Lidia Usnarska-Zubkiewicz

Tomasz Wrobel

Ajay Major

Make your next move.